Key clinical point: The combination of bempegaldesleukin and nivolumab produced durable responses in patients with previously untreated metastatic melanoma.

Major finding: The overall response rate was 53%, most responders were still in response at a median follow-up of about 19 months, and the median progression-free survival was not reached.

Study details: A phase 1/2 trial of 41 melanoma patients.

Disclosures: The trial is sponsored by Nektar Therapeutics in collaboration with Bristol-Myers Squibb. Dr. Diab disclosed relationships with Nektar, Celgene, CureVac, Idera, and Pfizer.